<?xml version="1.0" encoding="UTF-8"?>
<p id="Par5">All these approaches contribute to the impressive safety of transfusion from 
 <italic>recognized</italic> infections in the developed world [
 <xref ref-type="bibr" rid="CR9">9</xref>]. Pathogen reduction processes for labile blood components are proactive solutions but remain aspirational, as they are not yet available for all components, and will not be potent against all agents. Further, consensus on the health economic justification for pathogen reduction is absent when viewed from a societal perspective.
</p>
